• International Society of Paediatric Oncology Europe Neuroblastoma


BEACON is a randomised study for patients with refractory or relapsed neuroblastoma. It will compare the benefit of adding bevacizumab (an antibody that blocks angiogenesis) to chemotherapy with temozolomide or the combination of temozolomide and irinotecan. There will be four different treatment groups.


cr 116148

Further information (Cancer Research UK)

Please note that this is a clinical trial and is only open at a limited number of centres.

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information


SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.